Rheumatology
Conference Coverage
Reduced-frequency methotrexate monitoring causes no harm
Laboratory blood test results were similar despite moving from once every month to about once every 3 months or about once every 5 months during...
From the Journals
Do NSAIDs negate bone effect of bisphosphonates?
An exploratory post hoc analysis of data from a randomized clinical trial found women taking clodronate plus an NSAID saw a 49% adjusted increase...
From the Journals
Intra-articular steroid/lidocaine injection improves hip arthritis pain, function
Over 6 months, mean improvement in hip pain intensity was greater in patients who received triamcinolone with lidocaine than in those who got best...
News from the FDA/CDC
Upadacitinib earns FDA approval for ankylosing spondylitis
Janus kinase inhibitor offers oral option for patients who have who have had an insufficient response or intolerance with one or more tumor...
From the Journals
Parents’ autoimmune diseases may affect children’s development
Type 1 diabetes and psoriasis in parents, and rheumatoid arthritis in mothers, are associated with increased risk for autism spectrum disorder and...
Conference Coverage
Use of bone densitometry to grade hip OA could be boon to diagnosis, prognosis
A novel, semi-automated scoring system enables dual energy x-ray absorptiometry scans of the hip to be graded and provide useful clinical...
Conference Coverage
Lupus may lead to worse stroke outcomes for women, but not men
Women with systemic lupus erythematosus (SLE) were 20% more likely to have a prolonged hospital stay and 28% less likely to have a routine home...
Conference Coverage
IBD risk ‘uncertain’ in biologic-treated AxSpA patients
“Enormous uncertainty” surrounds the risk of inflammatory bowel disease associated with biologic treatment in patients with axial...
From the Journals
Secukinumab’s antipsoriatic effects confirmed in U.S. patient population
Results from a postmarketing trial conducted solely at U.S. centers found similar, albeit lower, responses to secukinumab 300 mg than was noted in...
Conference Coverage
OARSI sets sights on classifying early-stage knee OA
“Early-stage knee OA classification criteria, we believe are critically required,” Gillian Hawker, MD, MSc, said at the OARSI 2022 World Congress...
News from the FDA/CDC
U.S. FDA warns of hidden drug ingredients in certain supplements products
The products are marketed to treat arthritis, muscle pain and other conditions and are sold online and in some retail stores with variations of...